Warfarin sodium or coumadin is the therapeutic drug of choice for maintenance anticoagulation therapy (1) . The use of warfarin has increased dramatically over the past 40 years and becomes the most popular oral anticoagulant used in the world (2) . The dosage required to achieve the desired therapeutic effect varies up to 120-fold between individuals, and there are no reliable means of prospectively identifying which patients will require either unusually high or low dosage (2) . Several genetic polymorphisms have been suggested as important contributors to this human variability (3) .
Of those genetic polymorphisms, cytochrome P4502C9 (CYP2C9) enzyme polymorphism leads to warfarin hypersensitivity presumably due to decreased metabolism of the S-enantiomer (4) . Allelic variants of the gene coding for CYP2C9, 2C9*2 [Arg144Cys] and 2C9*3 [Ile359Leu] were shown to increase sensitivity to warfarin in these patients (5) . Those two main variants were proposed to increase the anticoagulant effect of warfarin and decrease the mean daily dose required to maintain the international normalized ratio (INR) of the prothrombin time within the target therapeutic range (6) . However, the impact of racial differences on the kinetics of dose response or on drug efficacy is not well defined because few clinical trials take ethnic variation into account (7) . The pharmacogenomic effect of CYP2C9 polymorphisms is assessed in different populations.
MATERIALS AND METHODS
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from various countries using PubMed (www. pubmed.com) as search engine. The reports with complete data on the pattern of CYP2C9 polymorphism are selected. The allele frequencies reported from all detected reports were recorded and used as primary data for further analysis. The frequencies of the wild-type allele (CYP2C9*1) from the reports in healthy populations from various countries were analyzed using the population genetic epidemiology method similar to that of a previous study (8) . Briefly, the allele frequency difference between each pair of population was calculated and used for comparison. The correlation between the ethnic group population and the allele frequencies was assessed using regression analysis. A p value equal to or less than 0.05 was accepted as statistically significant.
Correlation Between CYP2C9 Polymorphism and Warfarin Dose Requirement
A literature review was performed on the reports concerning the correlation between the pattern of CYP2C9 polymorphism and warfarin dose requirement using PubMed (www.pubmed.com) as search engine. The case-control studies with complete data on comparison between the lowdose requirement subjects, maintenance dose 1.5 mg/week or less (cases), and controls are selected. The allele frequencies reported from all detected reports were recorded and used as primary data for further analysis.
The frequencies from all reports were analyzed using the meta-analytic method. Briefly, overall allele frequencies in the cases and controls were calculated. The overall risk estimation for comparing the subjects who do not have variants was then performed. The comparison between frequencies was performed using a proportional Z test. The correlation between the population race and the gene frequencies was also assessed using the regression analysis. A p value equal to or less than 0.05 was accepted as statistically significant.
RESULT
Pattern of CYP2C9 Polymorphism in Different Populations
Eight available reports concerning the pattern of CYP2C9 polymorphism among different healthy populations (9-16) were selected for further analysis in this study. The quoted CYP2C9 polymorphism pattern is shown in Table 1 . A sig-nificant correlation between the population ethnicity and the gene frequencies was detected in this study (p < 0.05).
Clinical Correlation Between CYP2C9 Polymorphism and Warfarin Metabolism
Four available case-control reports (17) (18) (19) (20) were selected for further analysis in this study. The quoted CYP2C9 variants pattern is shown in Table 1 . From those four case-control studies, 103 cases and 712 controls are evaluated. The overall frequencies of CYP2C9 variants for the cases and controls are 73.8% and 29.4%, respectively. The overall frequency in the cases is significant higher (2.5 times) than controls (p < 0.05). According to this study, 26.6% of subjects with CYP2C9 variants have a low dose requirement, while 5.1% of subjects without CYP2C9 variants have a low-dose requirement. From overall risk estimation, the subjects with CYP2C9 variants have 5.2 times higher risk to low dose requirement.
Concerning the variants frequency in the cases of different racial group populations, the frequency of CYP2C9 variants range from 38.5% to 88.2%. There is no significant correlation between the population races and the variant frequencies (r = 0.62, p = 0.37).
DISCUSSION
Variability of drug response among individuals is a well-recognized problem that may result in either under-or overtreatment of the patients (7) . At present, warfarin is the most common antithrombotic drug prescribed to control blood hemostasis in those with indications such as stroke, myocardial infarction, pulmonary embolism, and atrial fibrillation (7) . Because warfarin is a narrow therapeutic index agent, a small change in systemic concentration of the drug may lead to significant changes in pharmacodynamic response (4, 7) . Balancing the risks of bleeding with those of thrombosis is the aim of this oral anticoagulant therapy.
One of several factors underlying the variability in warfarin dose response in patients receiving this oral anticoagulant is genetic predisposition, especially the CYP2C9 polymorphisms (4) . Recently, several data on polymorphisms in metabolic enzymes have been integrated with physiologically based pharmacokinetic modeling as an approach to determine the resulting overall variability on warfarin therapy (3, 4) . A summa-tive analysis on the pharmacogenetic effect of CYP2C9 variants on warfarin dose requirement was performed.
The ethnic difference of CYP2C9 variant frequency was demonstrated. A significant low frequency of CYP2C9 variants among the Asian (Table 1) can be demonstrated. These findings agree with those mentioned by Yoon and colleagues (21) . Although screening for the CYP2C9 variant might be useful (6) , genotyping of the CYP2C9*2 allele is considered to be unnecessary in Asians, because this allele appears to be extremely rare or absent in this population (41).
The clinical correlation between CYP2C9 polymorphism and warfarin metabolism was also an-alyzed. Four available case-control reports were selected for this meta-analysis. CYP2C9 variants are strongly associated with low-dose warfarin requirement ( Table 2 ). This finding is confirmed by the recent report by Joffe and colleagues (20) . In addition, the difference in race of the population does not affect the variants frequency, implying a null racial effect.
In summary, the CYP2C9 variants have a strong effect on the warfarin dose requirement. This phenomenon is ethnically dependent. Due to the high variants frequency among the whites in the West, the investigation for CYP2C9 might be useful for this population, not in Asians, whose variants frequency is very low. 
